Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus EFIDAC 24 CHLORPHENIRAMINE MALEATE.
BENADRYL vs EFIDAC 24 CHLORPHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Chlorpheniramine maleate is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated allergic reactions. It also has anticholinergic and sedative properties due to central H1 receptor blockade.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
4 mg orally every 4-6 hours; maximum 24 mg/day.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life ranges from 14 to 25 hours (mean 20 hours) in adults; prolonged in hepatic or renal impairment (up to 50-60 hours in cirrhosis).
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted via feces (biliary).
Category C
Category C
Antihistamine
Antihistamine